Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
To evaluate the efficacy of 0.5, 1.0, 2.0 and 4.0 g/ day of CaPre™ in reducing fasting plasma serum triglycerides over a four week period in patients with mild-to-high hypertriglyceridemia as compared to the standard of care alone.
Epistemonikos ID: 784cba94873fb545f2b23e604fbc8e943d8cce82
First added on: May 10, 2024